Hepatitis C virus genotypes, reactivity to recombinant immunoblot assay 2 antigens and liver disease

Ishiguro, Hiroshi; Tamura, Ikuo; Kurimura, Osamu; Koda, Toru; Mizui, Masaaki; Tsuchie, Hideaki; Kurimura, Takashi

doi:10.1002/jmv.1890430303

Cited by 31 publications

(21 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It seems, therefore, likely that absence of anti-NS4 in RIBA-2 is sig nificantly associated with infection by HCV types other than type 1, as has been already suggested [8,16].…”

Section: Tm Samples and Methodsmentioning

confidence: 90%

“…Several reports have shown that genotype 1 strains are associated with more severe disease than are genotypes 2 and 3 and are less responsive to the IFN therapy [5,6], thus suggesting that identification of the viral genotype infecting the patient may be relevant for prognosis and clinical man agement. At the moment, it is unclear whether the current diagnostic assays may be less efficient in detecting infec tions by HCV genotypes other than genotype 1 [7][8][9] or may perform with especial features (weak reactivities or indeter minate results) in patients infected by certain genotypes.…”

mentioning

confidence: 99%

“…These last two ge notypes are prevalent in Africa and genotype 6 is often found in the Far East [2]. Moreover, genotype 3 seems to be more prevalent among intravenous drug users (IVDU) than among blood donors in Southern Europe [3], Recently, three additional HCV genotypes (7)(8)(9) have been reported from South-Eastern Asia [4].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Typing of Hepatitis C Virus Antibody with Specific Peptides in Seropositive Blood Donors and Comparison with Genotyping of Viral RNA

León¹,

López²,

Elola³

et al. 1997

Vox Sanguinis

View full text Add to dashboard Cite

Background and objectives: Serotyping of antibody to hepatitis C virus (anti- HCV) with specific peptides has been developed as an alternate method for typing HCV infections. The method does not require a prior amplification of viral RNA sequences from the sample. Identification of the viral genotype may be relevant for prognosis and clinical management. Materials and methods: We used a previously described HCV serotyping assay (RIBA™ HCV Serotype SIA kit, Chiron Corp.) to investigate the serotype in 191 samples from blood donors selected for anti-HCV patterns (positive and indeterminate), ALT levels, and the presence or absence of viral RNA. The serotypes were compared with the genotypes obtained from typing the 5'-noncoding region of the viral RNA in 82 virémie samples. Results: We were able to obtain the viral serotype in 85% (114/134) of samples positive for anti-HCV but in only 3.5% (2/57) of the indeterminates. Lack of anti-NS4 in the sample was significantly associated with both untypable results and the presence of HCV serotypes other than serotype 1. The overall correlation with genotyping was 78% (64/82), rising to 95.5% (64/67) if only samples that could be both genotyped and serotyped were considered. The assay was easy to perform, gave reactivity patterns easy to interpret, and performed with high proficiency on anti-HCV-positive samples lacking detectable levels of viral RNA. Conclusions: This is a practical and useful method for typing HCV infections in the clinical setting. The poor ability of the Core peptides to give the serotype in samples lacking anti-NS4 and the lack of specific peptides to recognize HCV types other than 1, 2, and 3 are, however, some aspects of the method that need improvement in the future.

show abstract

“…It seems, therefore, likely that absence of anti-NS4 in RIBA-2 is sig nificantly associated with infection by HCV types other than type 1, as has been already suggested [8,16].…”

Section: Tm Samples and Methodsmentioning

confidence: 90%

mentioning

confidence: 99%

See 1 more Smart Citation

Typing of Hepatitis C Virus Antibody with Specific Peptides in Seropositive Blood Donors and Comparison with Genotyping of Viral RNA

León¹,

López²,

Elola³

et al. 1997

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…In this setting, patients with genotype 1b have a more severe and progressive liver disease [12][13][14][15] and are more likely to have a decreased likelihood of success with IFN therapy. [16][17][18][19] On the contrary, genotype 2a is more likely to be found among apparently healthy blood donors than in patients with CLD, 32 or in patients with mild CLD or in those who respond better to IFN therapy. [12][13][14][15][16][17][18][19] HCV might be a causative cofactor in the pathogenesis of B cell NHL: it is found in a significative percentage of some histotypes of NHL, 8,11,33,34 it is known to be able to infect B lymphocytes circulating in the peripheral blood (PB) 35 or infiltrating the bone marrow (BM) 36 and the liver, 37 and in vitro studies have shown its ability to infect a human BM-derived B cell line and the PB MNC from healthy subjects.…”

Section: Discussionmentioning

confidence: 99%

The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin’s lymphoma

et al. 1997

View full text Add to dashboard Cite

Increasing evidence suggests that the hepatitis C virus (HCV) might be involved in the pathogenesis of B cell non-Hodgkin's lymphomas (NHL). Since several HCV genotypes are currently identifiable and might be involved in the pathogenesis of different diseases (with different severity and responsiveness to therapy), the aim of our study was to assess the prevalence of viral genotypes in a group of patients with HCV-related NHL. Among 470 consecutive patients, 42 HCV Ab-positive cases were identified. HCV RNA could be detected by reverse transcriptase-polymerase chain reaction and genotyping performed in 31 of these cases. As compared to our control group (211 healthy blood donors and patients with chronic liver disease), a striking high prevalence of genotype 2ac was detected among B cell NHL (48.4 vs 9.0%), with a relative risk of infection of 5.37 (P Ͻ 0.0001). No major differences were observed in the distribution of NHL histotypes and in the clinical features among patients with genotype 1b (the other most frequent genotype) or 2ac, a part from a trend towards a higher percentage of liver disease and a lower likelihood of response to interferon for patients with genotype 1b. The same high prevalence of genotype 2ac has been recently reported in patients with mixed cryoglobulinemia (MC), monoclonal gammopathies, B cell NHL complicating MC and autoimmune hepatitis. All these data taken together suggest that genotype 2ac might be involved in the pathogenesis of lymphoproliferative and autoimmune disorders.

show abstract

“…The HCV core peptide sequences used in this study correspond to subtype 1a, and among the Spanish blood donors, subtype 1b is highly prevalent and subtype 1a relatively infrequent [8]. Although the HCV core protein contains type-specific epitopes, type-related differences in HCV antibody patterns mainly respond to antigenic diversity in nonstructural proteins [9, 10]and lack of anticore response in individuals infected by subtype 1b has not been related to sequence diversity in the immunodominant epitopes of the core antigen [11]. It seems, therefore, very unlikely that the HCV genotype distribution among our samples affected the results obtained with the HCV core multipeptide assay.…”

Section: Discussionmentioning

confidence: 99%

Use of Overlapping Synthetic Peptides to Characterize Samples from Blood Donors with Indeterminate Results to Hepatitis C Virus Core Antigen

León¹,

López²,

Elola³

et al. 1998

Vox Sanguinis

View full text Add to dashboard Cite

Background and Objectives: Despite recent improvements in supplemental assays, isolated reactivity to the hepatitis C virus (HCV) core antigen continues as one of the main problems in the confirmation of anti-HCV in blood donors. Reactivity against individual peptides from the c22-3 HCV recombinant antigen has been described as a useful tool for anti-HCV confirmation and donor counseling in such cases. Materials and Methods: We used a previously described set of overlapping peptides spanning the entire sequence of the c22-3 antigen to study 87 single serum samples from blood donors with reactivity for c22-3 antigen alone in second generation recombinant immunoblot assay (RIBA-2). All of them had been previously studied by RIBA-3, anti-HCV E2 EIA and HCV PCR. Results: 66 of the 87 samples studied could be classified as positive or negative for anti-HCV core using the multipeptide assay and such classification correlated well with the results obtained with RIBA-3 and the anti-E2 EIA. However, some discrepancies were found. The epitopes located along the N-terminal half of the molecule were mainly responsible for the specific antibody recognition but those enclosed within amino acids 1–15 were frequently involved in nonspecific reactivity. Some 38% of samples were considered to have specific antibody to the c22-3 antigen and a further 9% reacted for both anti-E2 and single core peptides that were often involved in specific antibody recognision. Conclusion: Testing of blood donor samples indeterminate to the HCV c22-3 antigen for reactivity against individual core peptides can confirm the presence of specific antibody and recognize nonspecific reactivity with certain cross-reacting epitopes. Third generation supplemental tests have reduced such false reactivity, but confirmation of samples with anticore alone is still necessary. Single reactivity to the HCV core antigen is likely to reflect prior exposure to the virus, but rarely active infection, either acute or chronic.

show abstract

Hepatitis C virus genotypes, reactivity to recombinant immunoblot assay 2 antigens and liver disease

Cited by 31 publications

References 25 publications

Typing of Hepatitis C Virus Antibody with Specific Peptides in Seropositive Blood Donors and Comparison with Genotyping of Viral RNA

Typing of Hepatitis C Virus Antibody with Specific Peptides in Seropositive Blood Donors and Comparison with Genotyping of Viral RNA

The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin’s lymphoma

Use of Overlapping Synthetic Peptides to Characterize Samples from Blood Donors with Indeterminate Results to Hepatitis C Virus Core Antigen

Contact Info

Product

Resources

About